Update
$Prelude Therapeutics(PRLD.US$ Prelude Therapeutics Announces Clinical Collaboration With Merck to Evaluate PRT3789 in Combination With Keytruda® (Pembrolizumab) in Patients With Smarca4-Mutated Cancers
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Trytosaveabit OP : Prelude Therapeutics- Co, Merck Each Retain All Commercial Rights to Their Respective Compounds, Including as Monotherapy or as Combination Therapies